Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

A role for rituximab in depleting B cells and compromising their antigen ... Type II mixed essential CRYOGLOBULINEMIA (MEC) is often associated with hepatitis C virus (HCV) infection, and leads ...

Methods 125 patients with SLE treated with rituximab over 12 years were studied prospectively. A major clinical response was defined as improvement of all active British Isles Lupus Assessment Group ...

Anti-nuclear antibodies and anti-smooth muscle actin antibodies were negative. Tests for hepatitis B, hepatitis C virus, and HIV were also negative. The necessity of liver biopsy remains controversial ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... particularly B-cell depleting agents like rituximab, or disease. HBsAg-positivity also confers ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...